首页> 外文会议>Reporters, markers, dyes, nanoparticles, and molecular probes for biomedical applications VII >Spectroscopic characterization of the binding mechanism of fluorescein and carboxyfluorescein in human serum albumin
【24h】

Spectroscopic characterization of the binding mechanism of fluorescein and carboxyfluorescein in human serum albumin

机译:人血清白蛋白中荧光素和羧基荧光素结合机理的光谱表征

获取原文
获取原文并翻译 | 示例

摘要

Fluorescein (FL) and some of its precursors have proven to be effective fluorescent tracers in pharmaceutical and medical applications owing to their high quantum yield of fluorescence in physiological conditions and their high membrane permeability. In order to protect FL from metabolic effects during the process of its delivery, human serum albumin (HSA) has been used as a carrier because of its compatibility with the human body. In the present work, we used spectroscopic methods to characterize the binding mechanisms of FL and one of its derivatives, 5(6)-carboxyfluorescein (CFL), in the HSA protein. The absorbance change of the two ligands (FL and CFL) was quantified as a function of the HSA concentration and the results indicate a moderate binding strength for the two ligands inside HSA (1.00 ± 0.12 × 10~4 M~(-1)). The quenching effect of FL(CFL) on the fluorescence intensity of W214 (the sole tryptophan in HSA) indicates that FL and CFL occupy Site I in the protein which is known to bind several hydrophobic drugs. By performing site-competitive experiments, the location of the ligands is determined to be similar to that of the anticoagulant drug warfarin. At higher ratios of [ligand]/[HSA], we observed an upward curvature in the Stern-Volmer plots which indicates that the ligands occupy more pockets in Site Ⅰ, close to W214. Our results indicate that both ligands bind in HSA with a moderate strength that should not affect their release when used as fluorescent reporters. The chemical and physical identities of the two ligands are also preserved inside the HSA binding sites.
机译:荧光素(FL)及其某些前体由于在生理条件下具有很高的量子荧光产量和较高的膜通透性,因此在制药和医疗应用中已被证明是有效的荧光示踪剂。为了保护FL在其递送过程中不受代谢影响,人血清白蛋白(HSA)由于与人体的相容性而被用作载体。在目前的工作中,我们使用光谱学方法表征了HSA蛋白中FL及其衍生物5(6)-羧基荧光素(CFL)的结合机制。根据HSA浓度对两个配体(FL和CFL)的吸光度变化进行定量,结果表明HSA内两个配体的结合强度中等(1.00±0.12×10〜4 M〜(-1)) 。 FL(CFL)对W214(HSA中唯一的色氨酸)的荧光强度的猝灭作用表明,FL和CFL占据了蛋白质中的位点I,已知该位点与几种疏水性药物结合。通过进行位点竞争实验,确定配体的位置与抗凝药物华法林的位置相似。在较高的[配体] / [HSA]比率下,我们在Stern-Volmer图中观察到向上弯曲,这表明配体在位点Ⅰ中占据更多的口袋,接近W214。我们的结果表明,两种配体均以中等强度结合在HSA中,当用作荧光报告分子时,该强度不应影响其释放。这两个配体的化学和物理特性也保留在HSA结合位点内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号